Tue, January 3, 2023

Yatin Suneja Upgraded (ACAD) to Strong Buy and Held Target at $22 on, Jan 3rd, 2023

  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. g-buy-and-held-target-at-22-on-jan-3rd-2023.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication
Yatin Suneja of Guggenheim, Upgraded "ACADIA Pharmaceuticals Inc." (ACAD) to Strong Buy and Held Target at $22 on, Jan 3rd, 2023.

Yatin has made no other calls on ACAD in the last 4 months.



There are 5 other peers that have a rating on ACAD. Out of the 5 peers that are also analyzing ACAD, 3 agree with Yatin's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Uy Ear of "Mizuho" Maintained at Hold with Decreased Target to $15 on, Wednesday, December 21st, 2022
  • Tessa Romero of "JP Morgan" Maintained at Hold with Decreased Target to $17 on, Monday, November 14th, 2022
  • Esther Hong of "Loop Capital" Initiated at Hold and Held Target at $17 on, Tuesday, November 1st, 2022


These are the ratings of the 2 analyists that currently disagree with Yatin


  • Salveen Richter of "Goldman Sachs" Downgraded from Hold to Strong Sell and Decreased Target to $12 on, Friday, November 4th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Decreased Target to $21 on, Thursday, November 3rd, 2022